Pangaja Paramsothy1, Denise J Jamieson, Charles M Heilig, Paula C Schuman, Robert S Klein, Keerti V Shah, Anne M Rompalo, Susan Cu-Uvin, Ann Duerr. 1. From CONRAD, Arlington, Virginia; the Centers for Disease Control and Prevention, Atlanta, Georgia; Wayne State University School of Medicine, Detroit, Michigan; Mount Sinai School of Medicine, New York, New York; Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine, Baltimore, Maryland; Brown Medical School, Providence, Rhode Island; and the Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract
OBJECTIVE: To examine the association of highly active antiretroviral therapy (HAART) with human papillomavirus (HPV) clearance and progression or regression of cervical cytological abnormalities in women with human immunodeficiency virus (HIV). METHODS: Five hundred thirty-seven women with HIV participating in the HIV Epidemiology Research Study, an observational, multisite cohort study, were evaluated semiannually from 1996 to 2000. Cervical Pap tests were collected for cervical cytology. Testing for HPV was conducted by polymerase chain reaction. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals (CIs). Number needed to treat (NNT) at 2 years was calculated for HAART. RESULTS: Among women with cervical squamous intraepithelial lesions, HAART was associated with an increased likelihood of HPV clearance (hazard ratio 4.5, 95% CI 1.2-16.3, NNT 22.4). Use of HAART was not associated with an increased likelihood of HPV clearance among women with normal cervical cytology (hazard ratio 1.7, 95% CI 0.9-3.1, NNT 6.5) or atypical squamous cells of undetermined significance cytology (hazard ratio 1.0, 95% CI 0.4-2.5, NNT 174.0). Use of HAART was not significantly associated with an increased likelihood of cervical cytologic regression (hazard ratio 1.3, 95% CI 1.0-1.7, NNT 10.9) or cervical cytologic progression (hazard ratio 0.7, 95% CI 0.6-1.0, NNT 12.8). CONCLUSION: Among women with preexisting abnormal cervical cytology, HAART was associated with enhanced HPV clearance but not with Pap test regression. Close monitoring of women with HIV for cervical cytologic abnormalities, regardless of HAART treatment status, is warranted. LEVEL OF EVIDENCE: II.
OBJECTIVE: To examine the association of highly active antiretroviral therapy (HAART) with human papillomavirus (HPV) clearance and progression or regression of cervical cytological abnormalities in women with human immunodeficiency virus (HIV). METHODS: Five hundred thirty-seven women with HIV participating in the HIV Epidemiology Research Study, an observational, multisite cohort study, were evaluated semiannually from 1996 to 2000. Cervical Pap tests were collected for cervical cytology. Testing for HPV was conducted by polymerase chain reaction. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals (CIs). Number needed to treat (NNT) at 2 years was calculated for HAART. RESULTS: Among women with cervical squamous intraepithelial lesions, HAART was associated with an increased likelihood of HPV clearance (hazard ratio 4.5, 95% CI 1.2-16.3, NNT 22.4). Use of HAART was not associated with an increased likelihood of HPV clearance among women with normal cervical cytology (hazard ratio 1.7, 95% CI 0.9-3.1, NNT 6.5) or atypical squamous cells of undetermined significance cytology (hazard ratio 1.0, 95% CI 0.4-2.5, NNT 174.0). Use of HAART was not significantly associated with an increased likelihood of cervical cytologic regression (hazard ratio 1.3, 95% CI 1.0-1.7, NNT 10.9) or cervical cytologic progression (hazard ratio 0.7, 95% CI 0.6-1.0, NNT 12.8). CONCLUSION: Among women with preexisting abnormal cervical cytology, HAART was associated with enhanced HPV clearance but not with Pap test regression. Close monitoring of women with HIV for cervical cytologic abnormalities, regardless of HAART treatment status, is warranted. LEVEL OF EVIDENCE: II.
Authors: Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson Journal: AIDS Date: 2011-01-02 Impact factor: 4.177
Authors: Michelle S Cespedes; Sarah L Kerns; Robert S Holzman; Paul J McLaren; Harry Ostrer; Judith A Aberg Journal: HIV Clin Trials Date: 2013 Nov-Dec
Authors: Deepa Reddy; Joseph Njala; Penny Stocker; Alan Schooley; Martiniano Flores; Chi-Hong Tseng; Colin Pfaff; Perry Jansen; Ronald T Mitsuyasu; Risa M Hoffman Journal: Int J STD AIDS Date: 2014-06-13 Impact factor: 1.359
Authors: David H Adler; Lisa Kakinami; Tebogo Modisenyane; Nkeko Tshabangu; Lerato Mohapi; Guy De Bruyn; Neil A Martinson; Tanvier Omar Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Kenneth H Fife; Julia W Wu; Kathleen E Squires; D Heather Watts; Janet W Andersen; Darron R Brown Journal: J Acquir Immune Defic Syndr Date: 2009-07-01 Impact factor: 3.731